Core Insights - Klotho Neurosciences, Inc. will participate in the Longevity Biotech 2025 conference in Boston on October 22-23, 2025, focusing on advancing longevity therapeutics [1][2] - The company aims to engage in one-on-one meetings with investors and potential partners during the event to discuss collaborations and therapeutic programs [2] - Klotho specializes in developing innovative cell and gene therapies targeting neurodegenerative and age-related disorders, leveraging a patented form of the "anti-aging" human Klotho gene [3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company listed on NASDAQ (KLTO) [3] - The company focuses on disease-modifying therapies for conditions such as ALS, Alzheimer's disease, and Parkinson's disease [3] - Klotho's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA therapeutics, along with genomics-based diagnostic assays [3]

Core Insights - Klotho Neurosciences plans to acquire assets from Turn Biotechnologies, focusing on longevity therapeutics and cellular reprogramming [1][2] - The acquisition includes Turn's Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system, developed at Stanford University [2] - The deal is contingent upon due diligence, a definitive agreement, and typical closing conditions [1] Technology and Applications - The technologies aim to restore tissue function and rejuvenate somatic cells, with potential applications in ophthalmology, dermatology, osteoarthritis, muscle health, immunology, and amyotrophic lateral sclerosis (ALS) [3] - Klotho's acquisition includes a partnership with a South Korean pharmaceutical company, potentially valued at up to $300 million [3] Strategic Implications - The collaboration highlights commercial interest in Turn's platform and its broad technological potential [4] - Post-acquisition, Klotho plans to rebrand to reflect its expanded mission and therapeutic capabilities [4] - Key personnel from Turn Biotechnologies will join Klotho's management and R&D teams after the transaction [4] Leadership Perspective - Klotho's CEO emphasized the transformative nature of the acquisition, linking the Klotho gene to anti-aging and neuroprotection [5] - The integration of Turn's ERA technology, which utilizes six RNA molecules, aims to enhance cellular rejuvenation capabilities [6]

Core Insights - Klotho Neurosciences, Inc. has signed a Letter of Intent to acquire select assets from Turn Biotechnologies, positioning itself as a leader in longevity therapeutics [1][4] - The acquisition includes Turn's ERA platform and eTurna RNA delivery system, aimed at rejuvenating somatic cells for various regenerative therapies [2][4] - Klotho will also gain a partnership with a South Korean pharmaceutical company valued at up to $300 million, highlighting the commercial potential of Turn's technology [3][4] Company Overview - Klotho Neurosciences focuses on developing innovative cell and gene therapies derived from the "anti-aging" Klotho gene, targeting neurodegenerative and age-related disorders [7] - The company aims to expand its therapeutic reach by integrating Turn's technologies, which utilize RNA molecules to reset cellular age [4][5] - Klotho plans to rebrand post-transaction to reflect its broadened mission in addressing aging and related diseases [4] Market Context - The longevity medicine market is rapidly growing, driven by an aging global population projected to reach 2.1 billion by 2050, significantly impacting healthcare costs [5] - Klotho aims to address aging at the cellular level, which is seen as a root cause of various age-related health issues [5]